Home Finance

FINANCE

October 24, 2025

Starna Therapeutics secures over ¥300M in Series B funding to advance in vivo CAR-T pipeline

The proceeds will be primarily used to upgrade and expand the company's extrahepatic targeted delivery platform, accelerate the clinical development of its in vivo CAR-T pipeline, and further solidify the company's innovative positioning in the field of RNA therapeutics.